Using leon’s nanotechnology platform, the companies plan to boost the solubility, bioavailability and stability of one of Takeda’s pipeline products. Positive results from the feasibility study could yield a “long-term collaboration” between the two groups, leon said.
The company touted its MJR technology as offering reformulation options that optimize an active pharmaceutical ingredient’s bioavailability and solubility. Leon described its platform as a one-step, continuous precipitation approach that is cost-effective and scalable.
“We are very pleased and proud that Takeda selected our MJR technology for a feasibility assessment with one of their compounds in development,” leon CEO Michael Mehler said in prepared remarks. “It is a major milestone for our company to win Takeda, a globally leading pharmaceutical company, as a partner and we look forward to this collaboration with the goal to contributing to bring valuable new medicines to patients worldwide.”